Tablet formation

Details Tablet formation Tablet formation

2006-09-19

2006-09-19

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S465000, C424S474000, C424S489000, C424S470000, C424S499000

Reexamination Certificate

active

07108864

ABSTRACT:
Disclosed is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, “binder” and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.

REFERENCES:
patent: 4013785 (1977-03-01), Weintraub et al.
patent: 4810775 (1989-03-01), Bendix et al.
patent: 4844907 (1989-07-01), Elger et al.
patent: 5211958 (1993-05-01), Akkerboom et al.
patent: 5225197 (1993-07-01), Bolt et al.
patent: 5256699 (1993-10-01), Murphy et al.
patent: 5358941 (1994-10-01), Bechard et al.
patent: 5519021 (1996-05-01), Young et al.
patent: 5563142 (1996-10-01), Palmer et al.
patent: 5585115 (1996-12-01), Sherwood et al.
patent: 5591714 (1997-01-01), Nagarajan et al.
patent: 6013280 (2000-01-01), Frisbee et al.
patent: 6177101 (2001-01-01), Martino et al.
patent: 6238695 (2001-05-01), Makooi-Morehead
Remington: The Science and Practice of Pharmacy 1995 (pp. 1395, 1397, 1398, 1411, 1617-1618).
Remington: The Science and Practice of Pharmacy, 19thEd. vol. 1, pp. 194-198 (1995).
Dictionary of Biochemistry and Molecualar Biology, 2nded. 1989, J. Stenesh pp. 269-270.
Clorpress Package Insert, Bertek Pharmaceutical, Jun. 1998.
Von. B. Asmussen et al, Drug Release in vitro from Digoxin Formulations with High Bioavailability, Arzneimittelforschung 1980;30(12) :2168-72.
A. F. Davis et al, Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate, Int. J. Pharm. (1991) , 76(1-2) , 1-8.
C. Doherty et al, The In-vitro pH-Dissolution Dependence and In-vivo Bioavailability of Frusemide-PVP Solid Dispersions, J.Pharm.Pharmacol. 41:73-78 (1989).
K.M. O'Driscoll et al, Chlorothiazide-Polyvinylpyrrolidone (PVP) Interactions: Influence on Membrane Permeation (Everted Rat Intestine) and Dissolution, Drug Development and Industrial Pharmacy. 8(4) , 547-564 (1982).
H. Fujioka et al, Biopharmaceutical Studies on Hydantoin Derivatives. III. Physico-chemical Properties, Dissolution Behavior, and Bioavailability of the Molecular Compound of 1-benzenesulfonyl-5,5-diphenylhydantoin and Anti-Pyrine, J. Phar. Dyn. Jul. 1982; 5(7) :475-484.
M. Fujii et al, Dissolution and Bioavailability of Phenobarbital in Solid Dispersion with Phosphatidylcholine, Chem. Pharm. Bull., 39 (7) 1886-1888 (1991).
T. Higuchi, Physical Chemical Analysis of Percutaneous Absorption Process from Creams and Ointments, J.Soc.Cosmet.Chem., 11 (1960) 85-97.
W. I. Higuchi et al, Drug Membrane transport Enhancement Using High Energy Drug-Povidone Coprecipitates, Proc.Int.Symp. on Povodone, pp. 71-79, 1993.
S.L. Raghaven et al, Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate, Int. J. Pharm. 193 (2000) 231-237.
N. Kondo et al, Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug, J.Pharm.Sci., 83 566-570 (1994).
T. Loftsson et al, The effect of polyvinylpyrrolidone and hydroxypropyl methylcellulose on HPβCD complexation of hydrocortisone and its permeability through hairless mouse skin, Europ.J.Pharm. Sci. 2 (1994) 297-301.
T. Loftsson et al, The effect of water-soluble polymers on aqueous solubility of drugs, Int. J. Pharm. 127 (1996) 293-296.
N.A. Megrab et al, Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation, J.Control.Rel. 36 (1995) 277-294.
H. Sekikawa et al, Dissolution Behaviors and Gastrointestinal Absorption of Phenytoin in phenytoin-Polyvinylpyrrolidone Coprecipitate, Chem.Pharm.Bull., 26, (1978) 3033-3039.
H. Suzuki et al, Some Factors Influencing the Dissolution of Solid Dispersions with nicotinamide and Hydroxypropylmethylcellulose as Combined Carriers, Chem.Pharm.Bull., 46 1015-1020 (1998).
M.T. Ledwidge et al, Effects of surface active characteristics and solid state forms on the pH solubiity profiles of drug-salt systems, Int.J.Pharm., 174 (1998) 187-200.
Abu T.M. Serajuddin et al, Influence of pH on Release of Phenytoin Sodium from Slow-Release Dosage Forms, J.Pharm.Sci. (1993) 82 (3) , 306-310.
H. Suzuki et al, Comparison of Nicotinamide, Ethylurea and Polyethylene Glycol as Carriers for Nifedipine Solid Dispersion Systems, Chem.Pharm.Bull., 45 (1997) 1688-1693.
K. Yamamoto et al, Dissolution Behavior and Bioavailability of Phenytoin from a Ground Mixture with Microcrystalline Cellulose, J.Pharm.Sci. 1976, 65 (10) : 1484-1488.
A.P. Simonelli et al, Inhibition of Sulfathiazole Crystal Growth by Polyvinylpyrrolidone, J.Pharm.Sci., 59 (1970) 633-638.
A.P. Simonelli et al, Dissolution Rates of High Energy Sulfathiazole-Povidone Coprecipitates II: Characterization of Form of Drug Controlling Its Dissolution Rate via Solubility Studies, J.Pharm.Sci., (1976) 65 (3) , 355-361.
R. Wald et al, Non-Crystallinity, Supersaturation and Relative Bioavailability: Experiences with a Non-Peptidic HIV-Protease Inhibitor, 10thAnnual Meeting of American Assoc. of Pharm. Sci., 1995, (24 pages).

Affiliated with

Also associated with

Rating

Tablet formation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tablet formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tablet formation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3594946